Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,597,011
  • Shares Outstanding, K 115,558
  • Annual Sales, $ 306,490 K
  • Annual Income, $ 94,180 K
  • 60-Month Beta 1.09
  • Price/Sales 5.26
  • Price/Cash Flow 16.48
  • Price/Book 3.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.22
  • Number of Estimates 3
  • High Estimate 0.23
  • Low Estimate 0.20
  • Prior Year 0.22
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.06 +4.06%
on 08/05/20
17.00 -20.06%
on 07/21/20
-2.91 (-17.61%)
since 07/10/20
3-Month
13.06 +4.06%
on 08/05/20
18.52 -26.64%
on 06/23/20
-0.14 (-1.02%)
since 05/11/20
52-Week
9.70 +40.10%
on 03/23/20
18.52 -26.64%
on 06/23/20
+1.16 (+9.33%)
since 08/09/19

Most Recent Stories

More News
Shuman Glenn & Stecker Investigates Corcept Therapeutics, Inc.

Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of Corcept Therapeutics, Inc. ("Corcept" or the "Company") (Nasdaq: CORT)....

CORT : 13.52 (-2.17%)
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

MRK : 80.89 (-0.02%)
BMY : 63.06 (+2.01%)
BLRX : 2.01 (-4.74%)
CORT : 13.52 (-2.17%)
Corcept: 2Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Tuesday reported second-quarter profit of $28.3 million.

CORT : 13.52 (-2.17%)
Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 13.52 (-2.17%)
Noteworthy Monday Option Activity: CORT, CWH, HELE

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Corcept Therapeutics Inc , where a total of 6,472 contracts have traded so far, representing...

CORT : 13.52 (-2.17%)
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020. The company will also host a conference...

CORT : 13.52 (-2.17%)
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing's Syndrome of Adrenal Origin

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 13.52 (-2.17%)
Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 13.52 (-2.17%)
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients

, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...

ONCY : 1.8700 (-2.60%)
ONC.TO : 2.53 (-1.94%)
PFE : 37.78 (-1.59%)
LLY : 150.63 (-1.55%)
NVTA : 29.16 (+1.29%)
CLVS : 4.91 (-4.84%)
CORT : 13.52 (-2.17%)
Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

MRK : 80.89 (-0.02%)
CORT : 13.52 (-2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CORT with:

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 14.31
1st Resistance Point 14.07
Last Price 13.52
1st Support Level 13.66
2nd Support Level 13.49

See More

52-Week High 18.52
Fibonacci 61.8% 15.15
Fibonacci 50% 14.11
Last Price 13.52
Fibonacci 38.2% 13.07
52-Week Low 9.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar